Journal article
Does continuing oral magnesium supplementation until delivery affect labor and puerperium outcome?
- Meier B Department of Obstetrics, Zurich University Hospital, Frauenklinikstrasse 10, CH-8091, Zurich, Switzerland.
- Huch R
- Zimmermann R
- von Mandach U
- 2005-05-19
Published in:
- European journal of obstetrics, gynecology, and reproductive biology. - 2005
Administration, Oral
Adult
Female
Humans
Labor, Obstetric
Lactation Disorders
Magnesium
Neuromuscular Agents
Obstetric Labor Complications
Postpartum Period
Pregnancy
Pregnancy Complications
Pregnancy Outcome
Puerperal Disorders
Time Factors
English
OBJECTIVE
To determine the labor and puerperal impact of continuing oral magnesium supplementation until delivery.
STUDY DESIGN
Single-center study with matched controls. In 40 pairs of healthy women with vaginally delivered singleton pregnancies, matched for maternal age, race and parity, maternal and neonatal outcome endpoints were compared in those receiving continuous oral magnesium aspartate supplementation 15-30 mmol/d for at least 4 weeks until delivery (for constipation, calf cramps, preterm contraction without cervical effacement or additional tocolytics) versus non-supplemented controls.
RESULTS
In the magnesium group labor was nonsignificantly longer (stage 1: 326.0+/-187.5 min versus 276.7+/-140.8 min, P = 0.19; stage 2: 52.0+/-44.5 min versus 43.5+/-44.0 min, P = 0.40) and maximum oxytocin dose nonsignificantly higher (14.5+/-9.4 [median 12.0; n=15] versus 10.5+/-6.9 [median 7.5] mU/min, P = 0.28; n = 10). Fewer women had afterpains (12 versus 20, P=0.11), required spasmolysis (3 versus 14, P = 0.005), or could breastfeed their infants exclusively at discharge (24 versus 34, P = 0.04).
CONCLUSION
Continuing oral magnesium supplementation until delivery does not significantly prolong labor or increase the oxytocin requirement, but it significantly impairs breastfeeding competence.
To determine the labor and puerperal impact of continuing oral magnesium supplementation until delivery.
STUDY DESIGN
Single-center study with matched controls. In 40 pairs of healthy women with vaginally delivered singleton pregnancies, matched for maternal age, race and parity, maternal and neonatal outcome endpoints were compared in those receiving continuous oral magnesium aspartate supplementation 15-30 mmol/d for at least 4 weeks until delivery (for constipation, calf cramps, preterm contraction without cervical effacement or additional tocolytics) versus non-supplemented controls.
RESULTS
In the magnesium group labor was nonsignificantly longer (stage 1: 326.0+/-187.5 min versus 276.7+/-140.8 min, P = 0.19; stage 2: 52.0+/-44.5 min versus 43.5+/-44.0 min, P = 0.40) and maximum oxytocin dose nonsignificantly higher (14.5+/-9.4 [median 12.0; n=15] versus 10.5+/-6.9 [median 7.5] mU/min, P = 0.28; n = 10). Fewer women had afterpains (12 versus 20, P=0.11), required spasmolysis (3 versus 14, P = 0.005), or could breastfeed their infants exclusively at discharge (24 versus 34, P = 0.04).
CONCLUSION
Continuing oral magnesium supplementation until delivery does not significantly prolong labor or increase the oxytocin requirement, but it significantly impairs breastfeeding competence.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.ejogrb.2005.04.002
- PMID 15899543
- Persistent URL
- https://folia.unifr.ch/global/documents/148418
Statistics
Document views: 20
File downloads: